Clinical trials: Psychosis
Parkinson's Disease Psychosis
Expanded Access of Pimavanserin for Patients With PD Psychosis
The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.
- Trial name
- NCT02762591
- Testing
- Pimavanserin tartrate
- Sponsor
- ACADIA Pharmaceuticals Inc.
Psychosis
To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
To demonstrate the relative bioequivalency of generic Haloperidol tablets versus Haldol in normal volunteers.
- Trial name
- NCT00946491
- Testing
- Haloperidol 10 mg Tablets (Cord Laboratories), Haldol 10 mg Tablets (McNeil Pharmaceuticals)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sandoz
Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.
- Trial name
- NCT00160147
- Testing
- bifeprunox
- Where
- 51 sites in United States, Czechia and 3 more
- Volunteers
- 60 people
- Sponsor
- Solvay Pharmaceuticals
Psychosis
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
This is a safety study evaluating the subjects who participated in previous Organon trials of the drug Org 24448. Patients will undergo a Screening visit, 1 or 2 Evaluation visits, and a possible Follow-Up period.
- Trial name
- NCT00780585
- Testing
- SCH 900460
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
- Trial name
- NCT01174004
- Testing
- pimavanserin tartrate
- Where
- 63 sites in United States, Canada
- Volunteers
- 199 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Bipolar Disorder, Bipolar Affective Psychosis
Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.
The primary purpose of the study is to assess the efficacy of Quetiapine extended release 600mg per day either as monotherapy or combined therapy in the treatment of patients with mania associated to Bipolar disorder.
- Conditions
- Bipolar Disorder, Bipolar Affective Psychosis, Mania, Manic Disorder
- Trial name
- EMMY (NCT00521365)
- Testing
- Quetiapine 600mg
- Where
- 7 sites in Mexico
- Volunteers
- 88 people
- Sponsor
- AstraZeneca
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psychosis
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
The purpose of this study is determine the minimal effective dose and the impact on: 1. treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients experiencing the first psychotic episode 2.
- Trial name
- NCT00449397
- Testing
- Quetiapine Fumarate
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Psychosis
Adherence in Adolescents and Children Treated on Quetiapine
Observational study aimed to describe the adherence in a population of adolescents and children treated on quetiapine from a first psychotic episode whose more important secondary objective is to identify possible predictive…
- Trial name
- NCT00680888
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Affective Psychosis, Bipolar, Manic Disorder
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks.
- Conditions
- Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania
- Trial name
- NCT00422123
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 51 sites in United States
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Affective Psychosis, Bipolar, Depression, Bipolar
Phase III/Seroquel SR Bipolar Depression Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Depression for 8 weeks.
- Conditions
- Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis, Psychoses, Manic-Depressive
- Trial name
- NCT00422214
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 54 sites in United States
- Volunteers
- 400 people
- Sponsor
- AstraZeneca